Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia

Summary

This dose-escalating phase I trial assesses for the first time the safety, the side effects and the harmlessness, as well as the therapeutical benefit of the new study drug GEM333 in patients with acute myeloid leukemia (AML). This AML was relapsed after previous therapy or was refractory to the standard therapy.

Timeline

Start

2018-04-11

Primary completion

2022-06-14

Completion

2022-06-14

Outcome

Outcome not reported

Stopped: “The actions and measures to be taken to restart the trial could not be implemented which made the premature termination inevitability.”

Drugs

Indications